These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 16753240

  • 1. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
    Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E.
    Vaccine; 2006 Jul 07; 24(27-28):5571-83. PubMed ID: 16753240
    [Abstract] [Full Text] [Related]

  • 2. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E.
    Vaccine; 2007 Jun 21; 25(26):4931-9. PubMed ID: 17499406
    [Abstract] [Full Text] [Related]

  • 3. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, Jansen KU, Allende M, Taddeo FJ, Skulsky D, Barr E.
    Vaccine; 2004 Aug 13; 22(23-24):3004-7. PubMed ID: 15297048
    [Abstract] [Full Text] [Related]

  • 4. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
    Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E.
    Vaccine; 2008 Dec 09; 26(52):6844-51. PubMed ID: 18930097
    [Abstract] [Full Text] [Related]

  • 5. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S, Alain S, Denis F.
    Gynecol Obstet Fertil; 2006 Dec 09; 34(7-8):647-55. PubMed ID: 16807045
    [Abstract] [Full Text] [Related]

  • 6. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
    Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA.
    J Infect Dis; 2009 Mar 15; 199(6):805-14. PubMed ID: 19199546
    [Abstract] [Full Text] [Related]

  • 7. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun 15; 16(89):91-4. PubMed ID: 17582921
    [Abstract] [Full Text] [Related]

  • 8. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P.
    Gynecol Oncol; 2009 Dec 15; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [Abstract] [Full Text] [Related]

  • 9. A human papillomavirus vaccine.
    Med Lett Drugs Ther; 2009 Dec 15; 48(1241-1242):65-6. PubMed ID: 16977280
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, Descamps DJ, Bock HL, Indian HPV Vaccine Study Group.
    J Obstet Gynaecol Res; 2010 Feb 15; 36(1):123-32. PubMed ID: 20178538
    [Abstract] [Full Text] [Related]

  • 11. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.
    Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, Kiviat NB, Jansen KU, Barber H, Smith JF, Tadesse A, Giacoletti K, Smith PR, Suhr G, Johnson DA.
    Vaccine; 2004 Jul 29; 22(21-22):2943-52. PubMed ID: 15246631
    [Abstract] [Full Text] [Related]

  • 12. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J, Future II Study Group.
    Curr Med Res Opin; 2008 Jun 29; 24(6):1623-34. PubMed ID: 18435868
    [Abstract] [Full Text] [Related]

  • 13. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E.
    J Infect Dis; 2007 Oct 15; 196(8):1153-62. PubMed ID: 17955433
    [Abstract] [Full Text] [Related]

  • 14. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.
    Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R, Suhr G, Barr E, Dicello A, Li W, Smith JF, Tadesse A, Jansen KU.
    Vaccine; 2004 Jul 29; 22(21-22):2936-42. PubMed ID: 15246630
    [Abstract] [Full Text] [Related]

  • 15. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected women from South Africa, Brazil and Botswana.
    Firnhaber C, Evans D, Friedman-Khalili R, Willliams S, Michelow P, Matlhagela K, Wester C, Grinsztejn B, Lockman S.
    J Clin Virol; 2011 Nov 29; 52(3):265-8. PubMed ID: 21908233
    [Abstract] [Full Text] [Related]

  • 16. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK, Alkhateeb FM.
    Ann Pharmacother; 2009 Apr 29; 43(4):740-4. PubMed ID: 19276314
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
    Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF, Reisinger KS, Protocol 016 Study Group.
    Pediatrics; 2006 Nov 29; 118(5):2135-45. PubMed ID: 17079588
    [Abstract] [Full Text] [Related]

  • 18. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A.
    J Infect Dis; 2003 Jul 15; 188(2):327-38. PubMed ID: 12854090
    [Abstract] [Full Text] [Related]

  • 19. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
    Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E.
    Cancer Epidemiol Biomarkers Prev; 2007 Apr 15; 16(4):709-15. PubMed ID: 17416761
    [Abstract] [Full Text] [Related]

  • 20. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.
    Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ.
    J Infect Dis; 2005 Dec 15; 192(12):2099-107. PubMed ID: 16288373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.